You are here: Home: PCU 3 | 2006: Audio Program Guide: PCU 3 | 2006 Audio
 
  Go to interview with Stephen J Freedland, MD
Go to interview with Michael J Zelefsky, MD
Go to interview with Mario A Eisenberger, MD
Go to interview with Paul F Schellhammer, MD
  To listen to individual tracks, click the on the track you wish to listen to.
To download tracks, right-click on the one you wish to download.
     
Freedland Stephen J Freedland, MD
Attending Physician, Durham VA Medical Center
Assistant Professor of Urology and Pathology
Duke University School of Medicine
Durham, North Carolina		  
  Click here to download the entire segment  
Track 1 Introduction
Track 2 Risk of prostate cancer-specific mortality after biochemical recurrence
Track 3 Selection of patients for early hormonal therapy
Track 4 Importance of regular surveillance for patients with lower-risk disease
Track 5 Predictive value of PSA doubling time for prostate cancer-specific mortality
Track 6 Factors influencing the early initiation of therapeutic interventions

Track 7 Use of combined androgen blockade versus LHRH monotherapy
Track 8 Salvage radiation therapy with or without combined androgen blockade
Track 9 Clinical use of intermittent androgen deprivation
Track 10 Paucity of clinical trials evaluating therapy at PSA relapse
Track 11 Role of high-dose bicalutamide for patients with PSA-only recurrence
audio
Track 12 Commonly asked questions about the management of PSA relapse
audio
Track 13 Efficacy and tolerability of docetaxel in hormone-refractory metastatic disease
audio
Track 14 Use of docetaxel for patients with high-risk, PSA-only disease
audio
Track 15 Impact of obesity on the development and natural history of prostate cancer
audio
Track 16 Counseling patients about lifestyle and dietary changes
audio
Track 17 Cardiac and bone health in patients receiving androgen deprivation therapy
audio
Track 18 Ongoing studies evaluating the effects of obesity and diet on prostate cancer
     
Zelefsky Michael J Zelefsky, MD
Chief, Brachytherapy Service
Memorial Sloan-Kettering Cancer Center
New York, New York		  
  Click here to download the entire segment  
Track 1 Introduction
Track 2 Key issues in multimodality radiation therapy and hormonal therapy for high-risk disease
Track 3 Impact of tumor grade and proliferation on response to radiation therapy
Track 4 Dose, administration and tolerability of radiation therapy and hormonal therapy
Track 5 Community variation in the quality of radiation therapy for prostate cancer
Track 6 Advances in the use of image-guided radiation therapy

Track 7 Selection and duration of hormonal therapy combined with radiation therapy
Track 8 High-dose bicalutamide as a potential alternative to total androgen blockade
Track 9 Optimal dose of radiation therapy and duration of hormonal therapy for high-risk disease
Track 10 Selection of patients for brachytherapy versus external beam radiation therapy
Track 11 Androgen deprivation for patients with intermediate-risk disease
audio
Track 12 Treatment of patients with PSA-only progression
audio
Track 13 Radiation therapy for patients with positive margins after prostatectomy
audio
     
Eisenberger Mario A Eisenberger, MD
R Dale Hughes Professor of Oncology and Urology
The Johns Hopkins University
Baltimore, Maryland		  
  Click here to download the entire segment  
Track 1 Introduction
Track 2 Clinical trial of adjuvant docetaxel/prednisone for high-risk disease after prostatectomy
Track 3 Efficacy and toxicity of adjuvant docetaxel/prednisone
Track 4 Fatigue, alopecia and GI toxicity associated with docetaxel/prednisone
Track 5 Improvement in time to PSA relapse in a pilot study of adjuvant docetaxel for patients with high-risk disease
Track 6 Immediate versus deferred adjuvant leuprolide with or without docetaxel for patients at high risk of relapse after prostatectomy

Track 7 Clinical and biochemical progression as trial endpoints
Track 8 Immediate versus delayed hormonal therapy
Track 9 Use of chemotherapy for patients with hormone-refractory, PSA-only disease
Track 10 Prostate cancer as a chemotherapy-sensitive disease
Track 11 Novel therapeutic strategies in prostate cancer
audio
Track 12 Utilization of PSA doubling time in treatment decision-making
audio
Track 13 Potential role of bevacizumab in the management of prostate cancer
audio
Track 14 Role of medical oncologists in advancing prostate cancer research
audio
Track 15 Developing agents targeting the androgen receptor
audio
     
Schellhammer Paul F Schellhammer, MD
Professor of Urology
Eastern Virginia Medical School
Norfolk, Virginia		  
  Click here to download the entire segment  
Track 1 Introduction
Track 2 A clinical investigator’s experience with the diagnosis and treatment of prostate cancer
Track 3 Differences in reaction to prostate cancer versus other chronic diseases
Track 4 Coping with the fear and uncertainty associated with prostate cancer
Track 5 Translating personal experience with prostate cancer to patient care
Track 6 Clinical benefit of docetaxel in prostate cancer

Track 7 Barriers and initiatives to increase clinical trial participation
Track 8 Use of PSA doubling time to identify candidates for clinical trials
Track 9 Selection of hormonal therapy when sexual functioning is not a patient concern